The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Ms Deanne Miller (General Counsel, Company Secretary, Chief Op. Officer) ...

Synovial sarcoma and MRCLS are rare and often aggressive cancers with limited treatment options. Synovial sarcoma is a soft ...

Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

INVINCIBLE-3 Study: a Phase 3 open-label, randomized study testing INT230-6 as monotherapy compared to the SOC drugs in second and third line treatment for certain soft tissue sarcoma subtypes. The ...

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 ...

The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.

Leading the charge was Xero (ASX:XRO), which soared 6 per cent after the accounting software company revealed a stellar ...

The addition of Dr. Michael Ferguson is welcomed news for countless families battling some of the more rare and aggressive childhood cancers.

If I only have around three years left to live, what's the point in A-levels?" According to bone and soft tissue cancer ...

Marryatt was diagnosed with Ewing sarcoma, which is a type of tumor that begins as a growth of cells in the bones and soft ...